-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
BioXcel Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2017 to 2024.
- BioXcel Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$10.9M, a 51.2% increase year-over-year.
- BioXcel Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$59.6M, a 66.7% increase year-over-year.
- BioXcel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$59.6M, a 66.7% increase from 2023.
- BioXcel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$179M, a 8.02% decline from 2022.
- BioXcel Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$166M, a 55% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)